Glycemic, renal, and graft outcomes with dulaglutide versus multiple daily insulin therapy after kidney transplantation in type 2 diabetes
Authors' conclusion
Once-weekly dulaglutide successfully replaced prandial insulin after kidney transplantation, providing better long-term glycemic stability, greater weight reduction, improved renal parameters, and similar graft outcomes, while reducing injection burdens.
Study context
- Population
- Kidney transplantation recipients with preexisting T2D, transplanted between 2016 and 2022after matching, analysed
- Participants
- 142 recipients
- Exposure
- Basal insulin plus dulaglutide vs multiple daily injection (MDI) insulin regimen
- Basal insulin/dulaglutiden = 71
- MDIn = 71reference
- Outcome
- Change in HbA1c
- Follow-up
- 24 months
Methodological detailspropensity-score matched 1:1, real-world
- Propensity-score matched 1:1
- Real-world
Main finding
As reported in the abstract
Basal insulin/dulaglutide
+0.06
% [+0.7 mmol/mol]
MDI
+0.61
% [+6.7 mmol/mol]
P = 0.02
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Weight changeGreater weight reduction with basal insulin/dulaglutide | P < 0.0001 |
eGFR
- Improvements in eGFR with basal insulin/dulaglutide; differences not statistically significant after matching
Kidney graft outcomes
- Not significantly different between the two groups
Original publication
Glycemic, renal, and graft outcomes with dulaglutide versus multiple daily insulin therapy after kidney transplantation in type 2 diabetes. Diabetes Res Clin Pract. Published 30 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →